We have a broad product portfolio ranging from newly discovered novel gene targets to compounds in Phase 2/3 clinical trials.

CANCER

	Omacetaxine mepesuccinate
	CML T315I+
	CML TKI resistant
	CML+TKI combination
	MDS
	AML
	Quinamed¨
	Prostate Cancer
	Breast Cancer
	Ovarian Cancer
	CXS-299
	Solid Tumors